Publications by authors named "Michelon I"
Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated meta-analysis, we explore the effectiveness of T-DXd in a large subset of patients with HER2-positive BC and CNS disease.
Methods: A systematic search was made on September 16th, 2024, for studies investigating T-DXd in the scenario of HER2-positive BC and brain metastases (BMs) and/or leptomeningeal disease (LMD).
Article Synopsis
- Sacituzumab Govitecan (SG) has shown significant clinical benefits for breast cancer patients but is associated with considerable toxicity.
- A meta-analysis of seven studies included 928 patients on SG and highlighted high rates of adverse events, particularly neutropenia (70%) and grade ≥3 neutropenia (46%).
- The findings suggest a need for careful monitoring and management of side effects when using SG, as it poses a higher risk of neutropenia, diarrhea, and anemia compared to standard treatment options.
Article Synopsis
- A systematic review and meta-analysis were conducted to evaluate the safety and efficacy of osimertinib in non-small-cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor mutations.
- The analysis included 15 studies with 594 patients, revealing common mutations such as G719X and L861Q, and determining key metrics like a 51.30% objective response rate (ORR) and a median progression-free survival of 9.71 months.
- Osimertinib was found to be generally safe, with only 21.77% of patients experiencing serious adverse events, showing promise for treating NSCLC with these uncommon mutations.
Article Synopsis
- Recent advancements in antibody-drug conjugates (ADCs) have improved outcomes for patients with HER2-low-expressing breast cancer, a group that previously lacked effective targeted therapies.
- A systematic review and meta-analysis was conducted to evaluate the effectiveness of various ADCs, including trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in treating HER2-low advanced or metastatic breast cancer, pulling data from multiple reputable sources.
- The findings revealed that patients treated with T-DXd had significantly better outcomes in terms of objective response rate, disease control rate, and overall survival compared to those receiving traditional treatment options, highlighting the potential of ADCs as effective therapies.
Article Synopsis
- There is no standard treatment for patients with locally advanced head and neck squamous cell carcinoma (LA HNSCC) who cannot tolerate cisplatin-based therapies, prompting a systematic review for alternative options.
- The review analyzed 24 studies involving 4,450 patients, finding that cetuximab combined with radiotherapy was the most common treatment, followed by carboplatin with radiotherapy, showing varied median overall survival rates.
- The findings suggest a need for diverse treatment combinations and emphasize the necessity for more clinical studies to explore effective options for this patient group.
Article Synopsis
- A systematic review and meta-analysis were conducted to evaluate the effectiveness of retreating advanced non-small-cell lung cancer (NSCLC) patients with EGFR-tyrosine kinase inhibitors (TKIs), analyzing 19 studies with a total of 886 patients.
- The pooled results indicated a median overall survival (OS) of 11.7 months and a progression-free survival (PFS) of 3.2 months, with an overall response rate (ORR) of 15% and disease control rate (DCR) of 61%.
- While the analysis highlighted the benefits of EGFR-TKI retreatment, especially with 3rd generation TKIs, it faced limitations due to heterogeneity in data and the inability to conduct certain
Background: Trastuzumab deruxtecan (T-DXd) has shown promising results in patients with breast cancer brain metastases (BCBMs). We conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of T-DXd in the human epidermal growth factor receptor 2 (HER2)-positive BCBM population.
Patients And Methods: We searched PubMed, Embase, and Cochrane Library databases as well as American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and San Antonio Breast Cancer Symposium (SABCS) websites for clinical trials (CTs) and observational studies evaluating T-DXd in patients with HER2-positive BCBM.
The long-lived xenon isomers Xe and Xe are of interest for the GAMMA-MRI project, which aims at developing a novel imaging modality based on magnetic resonance of polarized unstable tracers. Here, we present the steps leading to and following the production of these two isomers via neutron irradiation of highly-enriched Xe and Xe gas samples at two high-flux reactors, the High-Flux Reactor (Réacteur à haut flux, RHF) at the Institut Laue-Langevin (ILL) and the MARIA reactor at the National Centre for Nuclear Research (NCBJ). We describe the experimental setups and procedures used to prepare the stable xenon samples, to open the irradiated samples, and to transfer xenon isomers into reusable transport vials.
View Article and Find Full Text PDFCOVID-19 outcomes in patients with sickle cell disease and sickle cell trait compared with individuals without sickle cell disease or trait: a systematic review and meta-analysis.
EClinicalMedicine
December 2023
Background: Clinical manifestations and severity of SARS-CoV-2 infection in individuals with sickle cell disease (SCD) and sickle cell trait (SCT) are not well understood yet.
Methods: We performed a systematic review and meta-analysis to assess COVID-19 outcomes in individuals with SCD or SCT compared to individuals without sickle cell disease or trait. An electronic search on PubMed, Embase, and Cochrane Library was performed on August 3, 2023.